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Abstract. 
 
Mechanisms that regulate the transition of 
metastases from clinically undetectable and dormant to 
progressively growing are the least understood aspects 
 
of cancer biology. Here, we show that a large (
 
z
 
70%) 
reduction in the urokinase plasminogen activator re-
ceptor (uPAR) level in human carcinoma HEp3 cells, 
while not affecting their in vitro growth, induced a pro-
tracted state of tumor dormancy in vivo, with G
 
0
 
/G
 
1 
 
ar-
rest. We have now identiﬁed the mechanism responsi-
ble for the induction of dormancy. We found that uPA/
uPAR proteins were physically associated with 
 
a
 
5
 
b
 
1, 
and that in cells with low uPAR the frequency of this 
association was signiﬁcantly reduced, leading to a re-
duced avidity of 
 
a
 
5
 
b
 
1 and a lower adhesion of cells to 
the ﬁbronectin (FN). Adhesion to FN resulted in a ro-
bust and persistent ERK1/2 activation and serum-inde-
pendent growth stimulation of only uPAR-rich cells. 
Compared with uPAR-rich tumorigenic cells, the basal 
level of active extracellular regulated kinase (ERK) 
was four to sixfold reduced in uPAR-poor dormant 
cells and its stimulation by single chain uPA (scuPA) 
was weak and showed slow kinetics. The high basal 
level of active ERK in uPAR-rich cells could be 
strongly and rapidly stimulated by scuPA. Disruption of 
uPAR–
 
a
 
5
 
b
 
1 complexes in uPAR-rich cells with anti-
bodies or a peptide that disrupts uPAR–
 
b
 
1 interactions, 
reduced the FN-dependent ERK1/2 activation. These 
results indicate that dormancy of low uPAR cells may 
be the consequence of insufﬁcient uPA/uPAR/
 
a
 
5
 
b
 
1 
complexes, which cannot induce ERK1/2 activity above 
a threshold needed to sustain tumor growth in vivo. In 
support of this conclusion we found that treatment of 
uPAR-rich cells, which maintain high ERK activity in 
vivo, with reagents interfering with the uPAR/
 
b
 
1 signal 
to ERK activation, mimic the in vivo dormancy induced 
by downregulation of uPAR.
Key words: tumor dormancy • uPAR • mitogen-acti-
vated protein kinase • integrin activation • ﬁbronectin
 
C
 
LINICAL
 
 experience in cancer patients indicates that
some primary cancers and most metastatic lesions
undergo a period of dormancy before entering a
stage of progressive growth. Although this may be the
most crucial step in cancer progression, the mechanisms
underlying the conversion from a dormant to an actively
growing state have not been elucidated. A prevalent hy-
pothesis envisions that to grow, cancer cells must acquire
the ability to induce angiogenesis (Folkman, 1995), and
that the proangiogenic phenotype must be dominant. In
some experimental cancer models, cancer cells within a
progressively growing primary cancer, and possibly cancer
infiltrating cells such as macrophages (Dong et al., 1997),
cleave plasminogen to generate a fragment that appears to
tip the balance toward angiogenic suppression resulting in
dormancy of existing micrometastases (O’Reilly et al.,
1994). Another model of tumor dormancy involves experi-
mental B cell lymphoma in which antibodies directed to
surface immunoglobulins act as agonists of signal trans-
duction pathways leading to a block in cancer cell growth
(Marches et al., 1998). Although interesting, this model
may be unique to this particular type of cancer.
In studying the role of the cell surface receptor for
urokinase type plasminogen activator (uPAR)
 
1
 
 in malig-
nancy, we discovered that uPAR downregulation renders
a human epidermoid carcinoma, HEp3, dormant (Kook
et al., 1994; Yu et al., 1997). These cancer cells expressing
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1. 
 
Abbreviations used in this paper:
 
 CAM, chorioallantoic membrane;
CLI, collagen type I; co-IP, coimmunoprecipitate; ERK, extracellular reg-
ulated kinase; FN, fibronectin; GPI, glycosyl phosphatidylinositol; IP, im-
munoprecipitate; LN, laminin; MAPK, mitogen-activated protein kinase;
RTK, receptor tyrosine kinase; scuPA, single chain uPA; uPAR, uroki-
nase plasminogen activator receptor; VN; vitronectin. 
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,
 
50% of the normal level of uPAR, grew indistinguish-
ably from parental cells in culture but, when inoculated
onto the chorioallantoic membrane (CAM) of chick em-
bryos and maintained by serial in vivo passages, entered a
period of protracted (
 
z
 
4 mo) dormancy. Using bromode-
oxyuridine incorporation assays and apoptosis measure-
ments in vivo, we determined that dormancy was the result
of a reduced proliferation rate rather than an increased
apoptotic rate (Yu et al., 1997). These and other published
results allow us to propose that uPA/uPAR may have two
complementary functions: a well established one as an ac-
tivator of the proteolytic cascade on the surface of cancer
cells (Mignatti and Rifkin, 1993), and another as a compo-
nent of a signal transducing assembly (Busso et al., 1994;
Fazioli et al., 1997; Chapman, 1997). While as an activator
of the proteolytic cascade, uPA/uPAR enhances local in-
vasion, intravasation, and metastasis formation (Ossowski
et al., 1991; Mignatti and Rifkin, 1993; Andreasen et al.,
1997; Kim et al., 1998), we postulate that in its signal trans-
ducing capacity uPAR is responsible for facilitating cancer
cell proliferation in vivo.
Several signal transduction complexes and pathways
have been shown to be activated by uPA binding to
uPAR. uPA has been shown to be a mitogen for some
cells (Kirchheimer et al., 1987; Rabbani et al., 1992). How-
ever, uPA is not directly mitogenic for HEp3 cells since
uPAR-rich, malignant HEp3 cells, in which the receptor
is saturated by endogenously produced uPA (Ossowski,
1992), proliferate in culture at a rate similar to that of cells
with low uPAR. Other examples involve interactions with
multiple, nonreceptor tyrosine kinases of the Src family
that have been coimmunoprecipitated by anti–uPAR anti-
bodies (Bohuslav et al., 1995; Konakova et al., 1998). In
some cases these appeared to have been activated (Kona-
kova et al., 1998). Recent reports have shown that binding
of uPA to uPAR in tumor or endothelial cells activates the
mitogen-activated protein kinases (MAPK), extracellular
regulated kinase (ERK) 1 and 2 (Konakova et al., 1998;
Nguyen et al., 1998; Tang et al., 1998). However, these
reports neither addressed the mechanism of signaling
through uPAR nor considered the implication of these
events during in vivo cellular processes such as tumor pro-
gression. Since uPAR lacks a transmembrane domain and
is anchored through a glycosyl phosphatidyl inositol (GPI)
anchor (Ploug et al., 1991), it is most likely that it forms
cis-interactions with other membrane proteins. In fact,
several reports involving immunocolocalization, reso-
nance energy transfer, and functional studies (Xue et al.,
1994, 1997; Wei et al., 1996) have shown that 
 
b
 
1, 
 
b
 
2, and
 
b
 
3 integrin receptor families may be candidates for such
interactions. The relevance of these interactions is under-
scored by the fact that many of these receptors (
 
a
 
1
 
b
 
1, 
 
a
 
5/
 
b
 
1, 
 
a
 
6
 
b
 
4, and others) activate intracellular signals coupled
to the pathways used by receptor tyrosine kinases (RTKs)
and non-RTKs, namely the Ras-Raf-ERK and/or the
Cdc42-Rac-JNK pathways (Wary et al., 1996, 1998; Maini-
ero et al., 1997). Integrin and RTK-mediated signals may,
in a complementary fashion, lead to a full activation of cell
survival and proliferation (Miyamoto et al., 1996; Yamada
and Geiger, 1997). For example, 
 
a
 
5
 
b
 
1 may cooperate with
EGF receptor–dependent signals to promote cell division
(Yamada and Geiger, 1997). Also, other integrin–ECM in-
 
teractions that activate Shc-ERK and Rac-Rho-JNK–depen-
dent pathways, promote cell division in vitro and in vivo
(Mainiero et al., 1997; Murgia et al., 1998). Recent evidence
shows that integrin activation can be strongly modulated
by a number of membrane proteins (Porter and Hogg,
1998), including uPAR, and that an increase in the state of
activation of integrins and modulation of avidity, may en-
hance the adhesive and growth properties of cells on ap-
propriate matrix proteins (Damsky and Werb, 1992; Mor-
tarini et al., 1992; Bazzoni et al., 1998; May et al., 1998). Work
by Wei et al. (1996) has shown that transfection of uPAR
into human kidney 293 cells, through a specific interaction
with the 
 
b
 
1 integrin blocked their adhesion to FN. This
block could be ameliorated by transfection of caveolin
into the uPAR-transfected 293 cells (Wei et al., 1999).
We have investigated the mechanism through which a
reduction in surface uPAR expression in HEp3 carcinoma
cells impairs their in vivo proliferation, resulting in a state
of protracted dormancy (Yu et al., 1997). We postulated
that reduced uPAR expression may diminish the fre-
quency at which this receptor interacts with integrins or
other transmembrane proteins, reducing the abundance of
active complexes and causing a deactivation of mitogenic
pathways. Our results demonstrate for the first time that
uPAR downregulation leads to abatement of uPA/uPAR/
 
a
 
5
 
b
 
1–dependent signal transduction, reducing the MEK/
ERK pathway activation and resulting in cancer cell dor-
mancy. In addition, our data underscore the relevance of
the signaling partnership between uPAR and integrins by
elucidating its possible role in tumor progression.
 
Materials and Methods
 
Reagents and Antibodies
 
DMSO, Triton X-100, NP-40, sodium orthovanadate, NaFl, Trizma,
Hepes, leupeptin, pepstatin, PMSF, BSA, collagenase type 1A, human fi-
bronectin (FN), collagen I, and vitronectin (VN) were purchased from
Sigma Chemical Co. Aprotinin and trypsin were from ICN Biomedicals
Inc. DME, OPTI-MEM medium, glutamine, antibiotics, and Lipofectin™
were from Gibco Laboratories. FBS was from JRH Biosciences,
COFAL-negative embryonated eggs were from SPAFAS, Inc.; protein
G–agarose beads were from Boehringer Mannheim Corp. Polyvinylidene
difluoride membranes and enhanced chemiluminescence (ECL) detection
reagents were from Amersham Life Sciences. Mek1 inhibitor PD98059
was from New England Biolabs Inc.; purified human single chain uroki-
nase type plasminogen activator (scuPA) was provided by Abbott Labo-
ratories. Purified soluble human uPA receptor (uPAR) was provided by
Dr. Francesco Blasi (Milan, Italy). mAbs: anti-phospho ERK 1/2 (anti-
phospho-Tyr 204; clone E4), anti-NH2-Jun Kinase (JNK) (clone G7,
phospho-Thr 183, and phospho-Tyr 185), anti-Shc (clone PG-797) were
from Santa Cruz Biotechnology Inc. Anti-ERK1/2 (clone MK12) and anti-
HCK (C18) mAbs were from Transduction Laboratories. Antiphosphoty-
rosine was from Upstate Biotechnology Inc. Anti-Grb2/sem5/ASH, anti-
CD29 
 
(
 
b
 
1 integrin), and anti–CD55/DAF mAbs were from NeoMarkers.
Anti-
 
b
 
1 activating mAb TS2/16 was from Endogen, and anti–
 
a
 
5 antibod-
ies, clone P1D6, was from Chemicon International Inc. Mouse IgG
 
1
 
(MOPC1) was from Sigma Chemical Co. Anti-human uPAR 3996 mAb
was from American Diagnostica. Anti-human uPAR mAb R2 was pro-
vided by Dr. Francesco Blasi (Universita Vita-Salute S. Raffaele, Milan,
Italy), rat anti-
 
b
 
1 and 
 
a
 
5
 
b
 
1 integrin blocking mAbs AIIB2 and BIIG2
(Werb et al., 1989), respectively, were provided by Dr. Caroline H. Dam-
sky (University of California San Francisco, San Francisco, CA), currently
available from the Developmental Study Hybridoma Bank, at the Univer-
sity of Iowa. Anti–mouse IgG mAb conjugated with HRP was from Vec-
tor Laboratories. Anti-rabbit IgG antibody and anti–HA mAb (clone
12CA5) were from Boehringer Mannheim. 
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Cell Lines and Cell Culture Conditions
 
Human epidermoid carcinoma HEp3 (T-HEp3) (Toolan, 1954) that were
tumorigenic and metastatic in the chick embryo and in nude mice were se-
rially passaged on CAMs and used as a source of tumorigenic cells. The
source of spontaneous dormant tumor cells (D-HEp3) were HEp3 cells
passaged in vitro 120–170 times (Ossowski and Reich, 1983). HEp3 cells
transfected with the expression vector LK444 (control clones, designated
LK5 and LK25) or HEp3 cells transfected with LK444 vector expressing
antisense uPAR mRNA (clones AS24, AS33, and AS48) in which surface
uPAR and uPAR mRNA were reduced by up to 70 and 80%, respec-
tively, was described previously (Yu et al., 1997). T-HEp3 or D-HEp3
cells were cultured in DME with 10% heat inactivated FBS (HI-FBS),
penicillin (500 U/ml), and streptomycin (200 
 
m
 
g/ml). G418 (400 
 
m
 
g/ml)
was added to LK25 and AS24 culture medium. Unless otherwise indi-
cated, all cells were routinely passaged using 0.05% trypsin/EDTA. LK5,
LK25, AS24, AS33, or AS48 cells were used between passage 1 and 10 in
culture.
 
Growth of Tumor Cells on CAMs
 
For in vivo experiments, T-Hep3, LK25, D-HEp3, or AS24 cells growing
in culture were detached with 2 mM EDTA in PBS, washed, and inocu-
lated on the CAMs of 9–10-d-old chick embryos. In some experiments, be-
fore inoculation, the cells were incubated for 40 min at 37
 
8
 
C with appro-
priate antibodies. To determine growth in vivo at different times
postinoculation, the thickened CAMs indicating tumor cell presence were
excised, weighed, and after mincing, dissociated into single cell suspen-
sions by incubation with type 1A collagenase for 30 min at 37
 
8
 
C. Tumor
cells, recognized by their very large diameter, were counted with a
hemocytometer. Cell viability was determined by trypan-blue exclusion.
All antibodies used in vivo or in culture were free of azide. The antibodies
used in vivo were tested for endotoxin content, using the Pyrogen-Plus
test from Biowhittaker, and found to have 
 
,
 
24 pg/ml. For serial passage
of T-Hep3 cells, 7-d-old CAM tumors were minced, and small amounts of
the mince were reapplied to fresh CAMs of 10-d-old chick embryos.
 
Detection of Integrins Expression by FACS
 
®
 
 Analysis
 
For surface expression of integrins, cells were detached with 2 mM EDTA
in PBS, resuspended in cold PBS with Ca
 
2
 
1
 
, Mg
 
2
 
1
 
, and 1% FBS at 10
 
7
 
cells/ml. Antibodies (P1D6, anti-
 
a
 
5; AIIB2, anti-
 
b
 
1) were added to 4 
 
3
 
10
 
5
 
 cells at 25 
 
m
 
g/ml and incubated at 4
 
8
 
C for 30 min. Controls were incu-
bated with isotype-matched rat or mouse IgG. After two washes, FITC-
conjugated goat anti–mouse or goat anti–rat (1:100) IgG were added and
the cells incubated for 30 min at 4
 
8
 
C, washed two times, fixed in 5% form-
aldehyde in PBS, and analyzed in FACS
 
®
 
 scan equipped with a laser (488;
Becton Dickinson).
 
Analysis of Cell Cycle Distribution in Culture and
In Vivo
 
For cells in culture, exponentially growing cells were detached with 2 mM
EDTA as described above. For cells in vivo, CAMs were inoculated with
1–2 
 
3 
 
10
 
6
 
 cells, and at indicated times, tumor cells were isolated as de-
scribed above, except that cells suspensions were obtained by incubation
with collagenase for 20 min. To remove red blood cells, cell suspensions
were layered on a 50% cushion of Percoll in 0.15 M NaCl, centrifuged for
15 min at 3,000 rpm, and the cells were collected from the top of the Per-
coll cushion, washed once by centrifugation, fixed in suspension with 70%
ice-cold methanol, incubated with 10 mg/ml RNAse for 30 min at 37
 
8
 
C,
washed, and incubated with 50 
 
m
 
g/ml propidium iodide in 0.1% Triton
X-100 and 0.1% sodium citrate. The cells were kept in the dark before be-
ing analyzed by FACS
 
®
 
 scan, Profile II from Coulter Corp.
 
Transient Transfection of HA-ERK2 Expression 
Vector, Immunoprecipitation (IP), and Detection by 
Western Blotting
 
Dormant and tumorigenic cells were plated in 100-mm dishes and trans-
fected with 5–10
 
 
 
m
 
g vector DNA expressing HA-tagged ERK2 (Mainiero
et al., 1997) using Lipofectin according to the manufacturer’s instructions.
After 24 and 48 h, cells were lysed using a buffer with 300 mM NaCl, 10%
glycerol, 20 mM Hepes, pH 7.6, 5 mM MgCl
 
2
 
, 1 mM EGTA, 1 mM DTT, 1
mM sodium orthovanadate, 10 mM NaFl, and a cocktail of protease inhib-
itors. For in vivo experiments, 24 h posttransfection with the HA-ERK–
expressing vector, the cells were inoculated (2.5 
 
3 
 
10
 
6
 
 cell/CAM) into
8-mm-diam Teflon rings placed on CAMs. After 24 h of growth in vivo, the
CAMs delineated by the rings were excised, slipped into tubes containing
lysis buffer, and snap-frozen in liquid N
 
2
 
. The tissues were homogenized,
centrifuged for 14 min at 14,000 rpm at 4
 
8
 
C, and the supernatants were an-
alyzed for HA-ERK and phospho-HA-ERK as follows: 250 
 
m
 
g of cell pro-
tein was incubated with 1 
 
m
 
g of anti–HA antibody (12CA5) for 1 h at 4
 
8
 
C
and for 1 h with protein G–agarose beads. The G beads were washed
three times, resuspended in 2
 
3
 
 sample buffer, heated for 10 min at 95
 
8
 
C,
electrophoresed on SDS-PAGE, transferred to PVDF membranes (see
below), and blotted with antibodies to HA or to phospho-ERK. The sig-
nal was developed using the ECL method.
 
Adhesion Assays
 
Matrix protein or polylysine plates, (96-, 24-, or 6-well) were coated with
matrix proteins at 0.5 to 10 
 
m
 
g/ml or as stated in individual experiments,
or with 4–8 
 
m
 
g/ml of polylysine (PL), incubated overnight at 4
 
8
 
C in PBS,
and blocked for 1 h at 37
 
8
 
C with 1 mg/ml BSA (BSA or PL was used as a
negative control). Cells were detached with 2 mM EDTA, resuspended in
DME at 5 
 
3 
 
10
 
5
 
/ml, and added (50 
 
m
 
l per 96-well tray) to wells coated
with FN and preincubated at 37
 
8
 
C with 50 
 
m
 
l of DME. After 30 min incu-
bation at 37
 
8
 
C, the wells were washed gently, fixed with methanol,
stained with 0.5% of crystal violet in water for 10 min, and washed exten-
sively with water. After microscopic inspection, 60 
 
m
 
l of 10% methanol
and 5% acetic acid solution was added to each well and, after 10 min, the
OD at 570 nm was measured in a microplate reader (Dynatech Labora-
tory Inc.). Adhesion to other extracellular matrix proteins was done in a
similar way except that VN, laminin (LN), or type I collagen were used
instead of FN. Cells used in testing the effect of AIIB2 (20 
 
m
 
g/ml), BIIG2
(20 
 
m
 
g/ml), or TS2/16 (10 
 
m
 
g/ml) antibodies, and MnCl
 
2
 
 (1.5 mM) were
prepared as above, but the DME contained 0.2 mg/ml BSA and 10 mM
Hepes. The cells were resuspended at 10
 
6
 
 cells/ml with or without anti-
bodies and incubated on a rocking platform for 30 min at room tempera-
ture. The medium was diluted to yield 2 
 
3 
 
10
 
4
 
 cells/100 
 
m
 
l and 100-
 
m
 
l ali-
quots were inoculated into wells of a 96-well plate, four wells per sample.
The effect of MnCl
 
2
 
 on cell adhesion was examined without preincuba-
tion. All cells were allowed to adhere to FN for 20 min at 37
 
8
 
C and pro-
cessed as above.
 
In Vitro Cell Proliferation Assays
 
LK25 or AS24 cells (0.8 
 
3 
 
10
 
5
 
) were plated into wells of 24-well plates and
cultured overnight with 10% serum. The medium was replaced in DME
with 10 mM Hepes and 1 mg/ml BSA with or without 10 
 
m
 
M PD98059
(stock prepared in 100% DMSO); and the control medium contained
0.05% DMSO. Cells in three wells per sample were counted every 24 h in
a Coulter counter, (Particle Counter, Model Z1; Coulter Corp.). To study
the effect of immobilized FN on the growth of T-Hep3, LK25, D-Hep3, or
AS24 cells in culture, cells detached from monolayers with EDTA were
seeded in 24-well plates coated with FN or BSA in DME with 10 mM
Hepes and 1 mg/ml BSA. Every 24 h the cells (three wells per sample)
were detached and counted using a Coulter counter.
 
ERK and JNK Activation Assays, Basal Level, and 
Effect of Treatments
 
To determine the basal level of ERK and JNK activation, subconfluent
monolayers of cells were either kept overnight in DME with serum or in
DME with 10 mM Hepes and 1 mg/ml BSA, scraped in PBS, centrifuged,
and the pellets were lysed with RIPA buffer (1% Triton X-100, 140 mM
NaCl, 10 mM Tris, 0.02% sodium azide, 0.1% SDS, 0.5% deoxycholate,
1 mM orthovanadate, 1 mM NaFl, 200 KIU/ml aprotinin, 1 
 
m
 
g/ml leupep-
tin, 1 
 
m
 
g/ml pepstatin, 1 mM PMSF) and extracted on ice for 20 min. The
lysates were centrifuged for 14 min at 14,000 rpm and the supernatants
were saved. Equal amounts of proteins of each cell lysate were electro-
phoresed on an SDS-PAGE and Western blotted using either anti–phos-
pho-ERK (p42/p44) or anti–phospho-JNK (p46/p54) antibodies. The p42/
p44 ERK protein levels were determined using an anti–ERK1 antibody.
To test the effect of scuPA on ERK activation, subconfluent cell mono-
layers were starved overnight in DME with Hepes and BSA, washed and
acid-stripped for 3 min using cold 0.05 M glycine-HCl in 0.1 M NaCl
buffer, pH 3, to remove uPAR bound uPA, and neutralized using 0.5 M
Tris-HCl, pH 7.8. The cells were incubated for 1–60 min with 1–80 nM 
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scuPA in the presence of 200 KIU/ml aprotinin to avoid protease-depen-
dent effects of uPA. In some experiments, acid-stripped cells without or
with added scuPA (10 nM) were incubated in presence of 10 
 
m
 
M PD98059
for 10 min. In another set of experiments, serum-starved but nonacid-
stripped cells were incubated for the indicated time points with 0.1–10 ng/
ml (
 
,
 
0.2 nM) of soluble uPAR in the presence of 200 KIU/ml aprotinin.
To study the effect of integrin ligation on ERK and JNK activation, 24 h
serum-starved cells were plated at 10
 
6 
 
on PL- (4 
 
m
 
g/ml), FN- (0.4–4 
 
m
 
g/ml)
or CL-I– (4 
 
m
 
g/ml) coated dishes (cells plated on PL attached, but did not
spread even after 90 min). At the indicated times, the cells were processed
as above. To test whether the antibody would interfere with FN activation
of ERK, 10
 
6
 
 cells were preincubated for 35 min at 37
 
8
 
C with 7 
 
m
 
g/ml of R2
anti–uPAR antibody (recognizes domain 3 of uPAR), or 5 
 
m
 
g/ml of anti–
uPAR 3996 antibody (recognizes domain 1, and blocks uPA binding), or 7
 
m
 
g/ml of isotype matched IgG, or 10 
 
m
 
g/ml of 
 
b
 
1-integrin blocking anti-
bodies (AIIB2), or with isotype-matched IgG, plated on surfaces coated
with a mixture of PL and FN and, after 20 min incubation at 37
 
8
 
C, were
analyzed for ERK activation. To test the effect of uPAR interaction with
 
b
 
1 integrin on ERK activation, T-HEp3, LK25, or AS24 cells were incu-
bated for 5–10 min with increasing doses (0.1–50 
 
m
 
M) of peptide 25 (P25;
AESTYHHLSLGYMYTLN-NH
 
2
 
) dissolved in DMSO, that was shown
to inhibit such interactions, but not to interfere with uPA or VN binding
to uPAR (Wei et al., 1996). Controls were treated either with 0.05%
DMSO alone or with a scrambled version of peptide 25 (NYHYLESSMT-
ALYTLGH-NH
 
2
 
). Regardless of treatment, to test for ERK activation,
the cells were placed on ice, lysed, and the lysates were analyzed by West-
ern blots as described above for scuPA treatment.
 
Surface Labeling with Sulfo-NHS-Biotin
 
Subconfluent monolayers were washed three times with cold PBS, and the
cells were incubated on ice for 20 min with 5 ml of 0.5 mg/ml sulfo-NHS-
biotin (Pierce Chemical Co.). The reaction was stopped by aspirating and
washing the cells twice with 10 ml of ice-cold PBS. The cells were scraped
in 1 ml of PBS-containing protease inhibitors, spun at 4
 
8
 
C, and the pellets
were lysed with a lysis buffer containing 1% Triton X-100, 50 mM
Hepes, pH 7.5, 150 mM NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, and protease in-
hibitors as described for RIPA buffer. Immunoprecipitation and biotin-
ylated proteins’ detection were performed as indicated below.
 
Immunoprecipitation and Western Blot of Integrins
and uPAR
 
Cells were extracted for 1 h with a lysis buffer containing 1% Triton X-100,
50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 1 mM
orthovanadate, 1 mM NaFl, and protease inhibitors as described for RIPA
buffer. Triton X-100 soluble and insoluble fractions of biotinylated or
nonbiotinylated surface proteins (400 
 
mg protein) were incubated with 4
mg of TS2/16 anti–b1, anti–a5b1 (BIIG2), anti–a5 (P1D6), anti–uPAR
(R2) antibodies, matched isotype IgG or no IgG overnight at 48C, precipi-
tated with protein G–agarose beads, and washed three times. The beads
were resuspended in 23 Laemmli sample buffer, heated to 958C for 10
min, and analyzed by Western blotting using anti–b1 integrin (anti–CD29)
antibody or anti–uPAR R2 antibody. For Western blotting analyses, after
SDS-PAGE, the proteins were electrotransferred to PVDF membranes,
the membranes probed with the primary and secondary antibodies, and
the signal was detected using enhanced chemiluminescence with ECL
(Amersham Life Sciences) and X-OMAT films (Eastman Kodak). When
indicated, the bands were quantitated by laser densitometry using
GelScan XL (Pharmacia Biotech Sverige). To detect surface biotinylated
proteins, after immunoprecipitation with appropriate antibodies, the im-
munoprecipitates were separated in SDS-PAGE (nonreducing) and trans-
ferred to PVDF membranes. After blocking 1 h at room temperature with
5% skim milk, the membranes were washed with Tris buffered saline
Tween 20 and incubated 1 h at room temperature with 1:2,000 dilution of
streptavidin conjugated with HRP (Boehringer Mannheim) in TBS 0.3%
BSA. The membranes were washed three times with TBS and the signal
was developed using the ECL method.
Results
Divergent In Vivo Behavior of HEp3 Cells Differing in 
Their Level of uPAR Expression
To study the mechanism responsible for dormancy in-
duced by downregulation of uPAR, we used T-HEp3 (a
mass culture prepared weekly from CAM tumors and
maintained in culture for up to 1 wk), LK5, and LK25 (two
clones of HEp3 cells transfected with a LK444 vector; Yu
et al., 1997) as cell lines with a full complement of uPAR
(uPAR-rich), and compared them to dormant cell lines
with low uPAR levels, which included D-HEp3 obtained
by prolonged passage of T-HEp3 cells in culture, (Os-
sowski and Reich, 1983), AS24, AS33, and AS48 clones of
T-HEp3 transfected with a vector expressing uPAR anti-
sense (Yu et al., 1997). Compared with T-HEp3, LK5, and
LK25 cells, the level of uPAR protein in D-HEp3 and
AS24, AS33, and AS48 cell lysates was reduced by z80%
(Fig. 1 A). A similar reduction in uPAR mRNA and sur-
face uPAR number was found previously (Yu et al., 1997).
We also showed (Yu et al., 1997) that while all cell types
with high uPAR (a total of five) grew rapidly on CAMs,
all cells in the group with low uPAR (five total) remained
dormant for months, suggesting that these differences
were not due to clonal selection. The dormancy was linked
to a z70% reduction in bromodeoxyuridine incorporation
into the DNA of tumor cells maintained in vivo, and not to
enhanced cell death (Yu et al., 1997), indicating reduced
proliferation.
To further analyze the proliferative failure in vivo, we
inoculated D-HEp3 and T-HEp3 cells on CAMs, excised,
and dissociated the CAMs, and either counted tumor cells
daily (Fig. 1 B) or subjected them to cell cycle analysis
(Fig. 1, C and D). The T-HEp3 cells, which formed expo-
nentially growing tumors, divided rapidly (six divisions in
6 d) on CAMs, whereas the number of D-HEp3, low
uPAR cells, which formed very small nodules, did not in-
crease (Fig. 1 B). Cell cycle analysis revealed that in com-
parison to T-HEp3 cells in culture (day 0), T-HEp3 cells in
vivo had a statistically significant larger percentage of cells
in S phase, a matching decline in the percentage of cells in
G0/G1 and a matching fraction of cells in G2/M (Fig. 1 C).
This change was noticeable as early as 24 h postinocula-
tion and was maintained throughout the 6 d of observa-
tion. In contrast, D-HEp3 uPAR-deficient cells in vivo un-
derwent a rapid increase in the percentage of G0/G1 cells, a
rapid decline in the proportion of cells in G2/M, and a
slower decline in the percentage of S phase cells (Fig. 1
D). There was no significant difference in the proportion
of cells in the different cell cycle phases between T and
D-HEp3 cells in culture, whereas already after 1 d on the
CAMs, the percentage of dormant cells in G0/G1 was sig-
nificantly larger than that of uPAR-rich cells, (P 5 0.005),
and on day 3, the percentage of cells in both G0/G1 and S
phases was significantly different (P 5 0.000 and 0.001, re-
spectively).
Exit from G0/G1 and entry into S phase is promoted by
growth factors that signal predominantly through the
ERK pathway. Thus, we examined whether this pathway
is altered in uPAR-deficient cells by comparing the basal
state of activation of the ERK1/2 in uPAR-rich and low
uPAR cells. Cells incubated in serum-free medium for 24 h
were tested for levels of ERK and active phosphorylated
ERK (ERK1-p44/ERK2-p42) proteins by Western blots.
Compared with the level of phospho-ERK in T-HEp3,
LK5, or LK25 cells, the level in D-HEp3, AS24, AS33, or
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duction) (Fig. 2 A), suggesting that the signal leading to
ERK activation is impaired in uPAR-deficient cells. How-
ever, it should be noted, that despite the low level of active
ERK, D-HEp3, AS24, AS33, or AS48 cells are capable of
rapid proliferation in culture, possibly because a lesser
level of activated ERK may be sufficient to initiate cell cy-
cle progression in culture, or because parallel mitogenic
pathways may be active. To distinguish between these pos-
sibilities, we interrupted the ERK pathway by blocking the
activation of its immediate upstream activator MEK-1
with a specific inhibitor (PD98059). After 1 h of treatment
with 10 mM PD98059, basal ERK phosphorylation was
strongly reduced in LK25 cells and almost completely
blocked in AS24 cells (Fig. 2 B, inset). Increasing concen-
trations of the compound induced a dose-dependent inhi-
bition of cell proliferation in both cell types (Fig. 2 B), in-
dicating that even at this low basal level, activation of
ERK contributed to a mitogenic signal in uPAR-deficient
AS24 cells in culture. Together, these results suggest that
uPAR may be involved in triggering or coordinating a sig-
naling mechanism that produces a powerful activation of
the MEK-ERK pathway that may be crucial for mitogenic
stimulus in vivo.
Is the Low Level of ERK Activation the Result of a 
Reduced uPA/uPAR Signaling Pathway?
Since in tumorigenic HEp3 cells 80–90% of uPAR is occu-
pied by endogenously produced uPA (Ossowski, 1992),
and since binding of uPA, scuPA, or amino terminal frag-
ment of uPA to uPAR is known to initiate signal transduc-
tion (Busso et al., 1994; Nguyen et al., 1998), we wished to
test whether removal of the endogenous ligand interrupts
the signal leading to ERK activation and whether its addi-
tion restores it. LK25 and AS24 cells stripped of endoge-
nous uPA were incubated for 5 min with increasing con-
centrations of scuPA and tested for ERK phosphorylation.
To avoid scuPA activation and protease-dependent ef-
fects, the reaction was carried out in the presence of 200
KIU/ml aprotinin. In LK25 cells, scuPA binding induced a
strong, dose-dependent increase in phospho-ERK levels,
with a maximal effect at z10 nM (Fig. 3 A, left). Neither
the basal nor the stimulated levels of phospho-ERK were
detectable in AS24 cells at the same time of exposure
(data not shown). However, after a 10 times longer expo-
sure of the blot (10 s versus 1 s used in Fig. 3 A, left) both
basal and scuPA-induced active ERK became detectable.
Densitometric analysis revealed that 1 nM concentration
of scuPA (approximately its Kd value) caused a maximal
(approximately fourfold) stimulation of active ERK in
LK25 cells, whereas causing no modulation in AS24 cells.
The highest concentration of scuPA (80 nM) added to
AS24 cells produced a large stimulation over the basal
level (Fig. 3 A, right), but it still represented only ,4% of
active ERK in LK25 cells (Fig. 3 A, left). This result sug-
gests that it is not the fold increase, but the absolute level
of active ERK that needs to be high enough to surpass the
required threshold for proliferation in vivo. Similar results
were observed when T-HEp3 was compared with D-HEp3
cells (data not shown). Cells stripped of endogenous uPA
had a very low level of active ERK that could be restored
by incubation with exogenous scuPA, but not in the pres-
ence of the MEK-1 inhibitor PD98059 (Fig. 3 B), indicat-
ing that as shown before (Nguyen et al., 1998) the uPA-
induced signal was propagated through the MEK1-ERK
pathway. Also, time dependence of ERK activation by
scuPA was different: whereas 10 nM scuPA induced a
large increase in the level of phospho-ERK in LK25 cells,
which at 10 min reached a plateau sustainable for at least
60 min, AS24 cells showed a less pronounced and much
delayed activation of ERK by scuPA, peaking at 30 min
and decreasing at 60 min (Fig. 3 C), suggesting that the
Figure 1. In vivo growth and cell cycle analysis of uPAR-rich
(tumorigenic) and uPAR-deficient (dormant) cell lines. (A)
Western blot of uPAR (R2 antibody, top) and ERK (loading
control) (MK12 antibody, bottom) protein in lysates (50 mg
protein each) of T-HEp3 (lane 1), D-HEp3 (lane 2), LK25
(lane 3), AS24 (lane 4), LK5 (lane 5), AS33 (lane 6), and
AS48 (lane 7) cells. Lanes 8–10, purified soluble uPAR
(suPAR) at 12, 60, and 120 ng, respectively (experiment was
repeated three times). (B) Growth of HEp3 cells on CAMs.
T-HEp3 (empty squares) or D-HEp3 cells (filled squares)
were inoculated on CAMs and at the indicated times live tu-
mor cells were counted (see Materials and Methods). Mean
and SD (n 5 4) of the number of cell divisions shown (experi-
ment done twice). (C and D) Cell cycle analysis. T-HEp3 (C)
and D-HEp3 (D) were inoculated on CAMs at 1–2 3 106/
CAM, and at the indicated times single tumor cell suspen-
sions were prepared and processed for FACS® analysis based
on DNA content (see Materials and Methods). The percent-
age of cells in each stage of the cell cycle is indicated: G0/G1
(empty bars), S phase (filled bars) and G2/M (striped bars).
Each result represents the mean and SEM for at least three
CAMs. Similar results were obtained in three additional experi-
ments. *P , 0.005, #P , 0.015, as determined by Kruskal-Wallis
statistics. A comparison of G0/G1 and S phases of T-HEp3 and
D-HEp3 cells after 3 d of growth on CAMs showed statistically
significant differences, P 5 0.000 and P 5 0.001, respectively.The Journal of Cell Biology, Volume 147, 1999 94
z80% lower uPAR level in AS24 cells is incapable of
evoking an optimal signal through this pathway.
a5b1 Integrin as a Potential Functional cis-Partner of 
the uPA/uPAR Complex
Interactions of uPAR with integrins are known to result in
integrin activation in leukocytes during in vivo transendo-
thelial migration (May et al., 1998) and in modulating inte-
grin function as adhesion receptors (Wei et al., 1996).
Therefore, we tested whether the approximately fivefold
difference in uPAR expression between tumorigenic and
dormant cells influences integrin activation and function.
As a test of function, adhesion of cells was measured on
immobilized extracellular matrix proteins, including FN,
LN, collagen type I (CLI), and VN. Adhesion of uPAR-
rich tumorigenic (T-HEp3 or LK25) cells to FN was al-
ways three to sevenfold greater than that of uPAR-defi-
cient, dormant cells (D-HEp3, AS24, or AS33 cells), and
this difference was maintained over a range of FN concen-
trations (Fig. 4 A, left and right panels). Adhesion to 0.5
mg/ml of FN revealed even greater differences (data not
shown), but cells adhering to 0.5 mg were easily detached
Figure 2. Phosphorylation of ERK1/2 in uPAR-rich and uPAR-
deficient cells and its role in cell growth in culture. (A). Activa-
tion of ERK. Confluent cultures were serum-starved for 24 h, in-
cubated with fresh serum-free medium for 5 min, scraped, lysed,
and analyzed by Western blotting (50 mg protein/lane) and tested
for phospho-ERK (top), and after stripping of the membrane, for
ERK1/2 (bottom) (experiment repeated six times). (B) Inhibi-
tion of growth by MEK-1 inhibitor. LK25 (empty squares) or
AS24 (filled squares) were seeded in 24-well plates (1.5 3 105
cell/well), grown in 10% FBS overnight, washed, and incubated
with daily medium changes for 72 h, with or without the indicated
doses of MEK-1 inhibitor-PD98059. The cells were detached and
counted in a Coulter counter. Shown are mean and SD of tripli-
cate determinations. Inset: LK25 and AS24 cell monolayers,
grown as in B, treated for 1 h without (control) or with 10 mM of
PD98059. Phospho-ERK levels shown: lanes 1 and 3, controls for
LK25 and AS24 cells, respectively; lanes 2 and 4, PD98059 treat-
ment of LK25 and AS24 cells, respectively (both experiments
were repeated three times).
Figure 3. Analysis of uPA/uPAR–dependent signaling to ERK.
(A) Effect of scuPA on phospho-ERK. Subconfluent cultures of
LK25 or AS24 in 6-well plates were serum-starved for 24 h, acid-
stripped (to remove uPAR-bound uPA), and incubated for 5 min
with the indicated doses of scuPA and 200 KIU/ml of aprotinin
(aprotinin was also used in B and C). The levels of phospho-
ERK1/2 and ERK (lower panels) were determined by Western
blot (see Materials and Methods); the exposure time in upper left
panel is 1 s and in the upper right panel is 10 s (the experiment
was repeated three times); the graphs show the Phospho-ERK/
ERK ratio (R) obtained by densitometric scanning. (B) Effect of
MEK-1 inhibitor on scuPA-induced ERK activation. LK25 or
AS24 serum-starved cells were pretreated for 15 min with 10 mM
of MEK-1 inhibitor PD98059, or medium alone. The monolayers
were acid-stripped, incubated with 10 nM scuPA or medium
alone, for 5 min, with or without 10 mM PD98059, lysed, and ana-
lyzed for phospho-ERK (upper panels) or ERK levels (lower
panels) (experiment was repeated twice). (C) Time dependence
of ERK activation by scuPA. LK25 or AS24 cell monolayers
were acid-stripped and incubated for the indicated times with 10 nM
scuPA. Phospho-ERK (upper panels) and ERK (lower panels)
levels were determined (experiment was repeated twice).Aguirre Ghiso et al. Role of uPAR, Integrins, and MAPK in Tumor Dormancy 95
by washes, making the experiments more difficult. The dif-
ferences (four to fivefold) in adhesion was maintained
when tumorigenic and dormant cells were plated on 5 mg/ml
of the 120-kD fragment of FN that lacks the a4b1 binding
site (data not shown), confirming the involvement of the
classical FN receptor. The uPAR-rich and low uPAR cells
showed no difference in adhesion to other matrix proteins;
both types of cells adhered well to CLI, but poorly to VN
and LN (results not shown). The difference in adhesion to
FN could not be explained by a difference in surface ex-
pression of FN-binding integrins, since their surface ex-
pression examined by FACS® analysis using antibodies to
a5 and b1 (Fig. 4 B), a3 and aV (results not shown), and
isotype-matched IgG as negative controls, showed that in
every instance, the percentage of positive cells and the
mean fluorescence intensity were similar or greater in the
uPAR-deficient, dormant cells (Fig. 4 B and results not
shown), suggesting that integrin function and not its sur-
face level regulate adhesion to FN. Although, in addition
to a5, the HEp3 cells express other FN-binding integrins,
Figure 4. Adhesion to FN and
analysis of integrin expression
and activation in tumorigenic
and dormant cells. (A, left) Ad-
hesion to FN. Cells (2.5 3 104
per well of 96-well plates, four
wells per experimental point)
were inoculated into wells
coated with FN, incubated at
378C for 30 min, fixed, and
stained with crystal violet (see
Materials and Methods), the dye
was extracted, and the absor-
bance was measured at 570 nm.
The inter-well absorbance differ-
ences were ,15%. (A, right)
Adhesion to FN of different tu-
morigenic (T-HEp3 and LK25)
or dormant (AS24, AS33, and
D-HEp3) cell lines (104 cells/
well) into FN-coated (10 mg/ml)
96-well plates. Adhesion was
measured after 20 min at 378C as
in A (left). (B) Surface expres-
sion of a5 and b1 integrins. Ex-
pression was measured using
FACS® analysis as described
in Materials and Methods.
The antibodies used: isotype-
matched mouse IgG-control for
a5; anti-a5 (P1D6); anti-b1
(AIIB2). Cells treated with rat
IgG similar to mouse IgG (not
shown). (C). Stimulation and in-
hibition of cell adhesion to FN.
Cells were incubated either with
b1 or a5b1 blocking antibodies
(AIIB2 or BIIG2, respectively)
or with stimulating (TS2/16)
anti-b1 integrin antibody, or
without antibodies, and inocu-
lated (104  cells/well) into FN-
coated (10 mg/ml) 96-well plates.
Adhesion was measured after 20
min at 378C as in A. The effect of
1.5 mM MnCl2 was tested with-
out preincubation. Adhesion in
medium without antibodies or
MnCl2 was considered 100% (ex-
periment was repeated three
times).The Journal of Cell Biology, Volume 147, 1999 96
such as a3 and aV (data not shown), the fact that no dif-
ference in adhesion of tumorigenic and dormant cells to
LN and VN was noted, suggests that these two integrins,
although able to pair with b1, do not play a major role in
the differential adhesion to FN, thus pointing to a5b1 as
the likely candidate. To test this possibility directly, we ex-
amined the effect of b1-activating antibodies (TS2/16) and
b1 (AIIB2) or a5b1 (BIIG2) function–blocking antibodies
on adhesion to FN of dormant and tumorigenic cells. We
found that adhesion to FN of D-HEp3 or AS24 cells was
increased by 67 and 85%, respectively, by TS2/16 antibody,
whereas the adhesion of T-HEp3 or LK25 cells was un-
affected (Fig. 4 C). Treatment of cells with 1.5 mM MnCl2,
which substantially increased the adhesion of dormant
D-HEp3 or AS24 cells to FN, did not affect the adhesion
of tumorigenic T-HEp3, or LK25 cells (Fig. 4 C) nor did it
affect the adhesion of dormant cells to CLI (data not
shown). Further support for a principal role for a5b1 inte-
grin in mediating adhesion of HEp3 cells to FN is found in
the observation that b1 and, more importantly, a5b1 func-
tion blocking antibodies (AIIB2 or BIIG2, respectively)
reduced the adhesion to FN of all tested cells by z70–
90%, indicating that regardless of the adhesion level (high
in uPAR-rich and greatly reduced in low uPAR cells), the
FN adhesion is predominantly mediated by a5b1 integrins
and that the contribution to adhesion of other FN-binding
integrins is marginal. Together, these results indicate that,
a large proportion of a5b1 integrins in dormant uPAR-
poor cells, although capable of being activated by Mn21 or
an activating antibody, are intrinsically inactive. In con-
trast, in malignant, uPAR-rich cells exposed to similar
conditions, the a5b1 integrins are maintained in a state
that allows for an optimal adhesion to FN.
Is the state of a5b1 integrin activation reflected in its
function as a signaling receptor? We found that T-HEp3
cells plated for 20 min on dishes coated with increasing
concentrations of immobilized FN, showed a dose-depen-
dent increase in the levels of active ERK as compared with
cells on PL-coated dishes (PL facilitates cell attachment
but avoids integrin engagement; Fig. 5 A, left). In contrast,
D-HEp3 cells showed only marginal activation of ERK at
20 min on FN-coated dishes (Fig. 5 A, right). In LK25 or
T-HEp3 cells, but not in dormant cells, FN activated ERK
at similar concentrations at which it stimulated adhesion
(data not shown and Fig. 5 A). ERK activation by FN in
LK25 cells was maximal at 20 min, and remained at almost
peak level for up to 90 min (Fig. 5 B, upper panel). In con-
trast, in AS24 cells, not only the magnitude of response
was greatly reduced, but also the activation of ERK did
not persist beyond 20 min (Fig. 5 B, lower panel). Some
activation of ERK was observed in cells plated on PL for
45 and 90 min (Fig. 5 B). This was most likely caused by in-
tegrin-independent cell adhesion or because of deposition
of endogenous FN matrix. It also has been reported that
integrin engagement may activate the JNK pathway to
promote cell cycle progression (Mainiero et al., 1997), but
we found a similar basal level of active JNK in dormant
and tumorigenic cells that was activated neither by FN
(Fig. 5 C) nor by CLI (results not shown).
We next tested whether FN/a5b1–dependent ERK acti-
vation leads to increased cell proliferation. In serum-free
medium, immobilized FN stimulated the growth of uPAR-
rich LK25 cells in a dose-dependent fashion (Fig. 5 D),
with doses even as low as 0.04 and 0.4 mg/ml producing sig-
nificant stimulation of growth. In contrast, the growth of
uPAR-deficient, dormant AS24 cells was only very mar-
ginally modulated, even by the highest FN concentration
used (Fig. 5 E). This difference in response to FN was also
observed with T-HEp3 and D-HEp3 cells (results not
shown). These same doses of FN differentially stimulate
ERK activation and adhesion in tumorigenic and dormant
cells (data not shown and Fig. 5, A and B). These results
strongly suggest that uPAR-deficient cells may have an
impairment in the activation pathway of MEK1/ERK by
an FN/a5b1/uPAR signaling mechanism.
Does Interaction between uPAR and a5b1 Play a Role 
in ERK Activation?
To answer this question, we first examined whether uPAR
and b1, a5, or a5b1 integrins were physically associated by
testing the ability of anti-b1,  a5, or a5b1 antibodies to
coimmunoprecipitate (co-IP) uPAR and of uPAR antibod-
ies to co-IP a5b1 integrins from cell lysates. Cell lysates
were IP-ed and Western blotted. IP with anti–b1 antibody
revealed a complex with uPAR, which was vastly reduced
in the D-HEp3 and AS24 cells as compared with T-HEp3
cells, reflecting, most likely, the low level of uPAR in these
cells (Fig. 6 A). All three cell type lysates contained simi-
lar amounts of b1 protein (Fig. 6 A, upper panel). In a sec-
ond approach, lysates of surface biotinylated cells were
IP-ed with anti–b1, a5, a5b1, and uPAR antibodies. Anti–
a5b1 (BIIG2) or a5 (P1D6) antibodies coimmunoprecipi-
tated 55-, 116-, and 150-kD bands, which correspond to
uPAR, b1, and a5 integrins, respectively (Fig. 6 B, left)
(two additional bands of z130 and 80 kD were also
present, but not yet identified). As shown before for b1 as-
sociation with uPAR, in spite of similar amounts of b1
(Fig. 6 C) and a5 integrins present on the surface of all
cells tested, the amount of uPAR in complex with a5b1
was 3.3–7-fold less in AS24 cells than in LK25 or T-HEp3
cells (Fig. 6 B). The identity of uPAR and b1 integrin was
verified by a parallel IP with anti–uPAR antibodies (Fig. 6
B, second lane) and anti–b1 antibodies (Fig. 6 B, right
panel). The ability of the different antiintegrin antibodies
to co-IP uPAR from biotinylated cells (Fig. 6 B, left and
right) suggests a plasma membrane association for these
proteins. It also shows that biotinylation does not prevent
the antibodies from recognizing their specific antigens.
Taken together these results, along with the results show-
ing inhibition of adhesion to FN by anti–b1 or a5b1 anti-
bodies, strongly support the presence of a functional sur-
face adhesion and signaling complex formed by uPAR and
a5b1 integrins, which is more prevalent on uPAR-rich
cells. Thus, the severe deficiency of dormant cells in inte-
grin a5b1 adhesive and signaling properties is most likely
due to the reduced number of active a5b1–uPAR com-
plexes on the surface of these cells.
We next examined whether the low level of ERK activa-
tion in uPAR-deficient cells can be corrected by exoge-
nously added, soluble uPAR (suPAR). Such an effect
would suggest that b1 integrin or other extracellular do-
mains of transmembrane proteins may serve as uPAR
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LK25 or AS24 cells were incubated for 5 min with increas-
ing concentrations of suPAR and tested for ERK phos-
phorylation. While not affecting ERK in LK25 cells, suPAR
induced a dose-dependent phosphorylation of ERK in
AS24 cells, with maximal stimulation occurring at 5 ng/ml
(z0.5 nM) (Fig. 7 A; T-HEp3 cells behaved like LK25 and
D-HEp3 like AS24, results not shown). The addition of
suPAR did not fully restore the level of ERK activation
found in uPAR-rich cells, suggesting that GPI-anchored
uPAR may be more effective in integrin activation. Taken
together, these results strongly suggest that a full comple-
ment of uPA/uPAR, through an interaction with a5b1 in-
tegrin, may be responsible for the high level of ERK acti-
vation in LK25 and T-HEp3 cells.
The observation (Fig. 3, A and C) that binding of scuPA
to uPAR increases the uPAR–integrin b1-mediated ERK
activation signal suggests that a change in uPAR confor-
mation may mediate this interaction. Therefore, we ex-
amined whether incubation of uPAR-rich cells with
anti–uPAR antibodies affects ERK activation by FN. Pre-
incubation of T-HEp3 or LK25 cells with mAbs (R2),
which recognize domain 3 of uPAR, strongly inhibited
FN-dependent activation of ERK, whereas irrelevant, iso-
type-matched IgG had little or no effect (Fig. 7 B). Anti-
body to domain 1 of uPAR also blocked ERK activation
but to a somewhat lesser degree (results not shown).
To further examine the notion that uPAR–b1 interac-
tion may be important for ERK activation, we treated
T-HEp3 and LK25 cells with a peptide (peptide 25) that
has been shown previously to interfere with the physical
and functional interaction of uPAR and b1 integrins (Wei et
al., 1996, 1999). Peptide 25, but not its scrambled version,
when added to adherent cells, was capable of reducing
ERK activation in a dose-dependent manner (Fig. 7 C; a
lower concentration [0.1 mM] was ineffective and 1 mM
was almost as effective as 5 mM [results not shown]). Pre-
incubation of suspended T-HEp3 cells with peptide 25, fol-
lowed by their plating on FN, produced a similar reduction
in ERK activation (Fig. 7 D) without diminishing the abil-
ity of cells to adhere to FN. A recently published report
(Wei et al., 1999) showed a similar lack of effect of peptide
25 on adhesion of uPAR and caveolin transfected 293 kid-
ney cells or smooth muscle cells to FN. ERK activation
could also be diminished by preincubation of T-HEp3 cells
with a blocking anti–b1 antibody. In this experiment the
cells remained adherent, as they were plated on a mixture
Figure 5. Modulation by FN
of ERK activation and cell
growth in tumorigenic and
dormant cells. (A) Activa-
tion of ERK by FN. 6-well
plates were coated with PL (4
mg/ml) or with 0.4 and 4 mg/ml
FN. HEp3 cells (left) or
D-HEp3 cells (right) (1 3
106 cells/well) were plated,
allowed to attach for 20 min,
lysed, and analyzed for phos-
pho-ERK (upper panels) and
ERK (lower panels) levels
(experiment was repeated
three times). (B) Time-
course of FN-induced ERK
activation. Cells plated into
wells precoated with 4 mg/ml
of PL or FN were incubated
for 10, 20, 40, or 90 min,
lysed, and examined for
phospho-ERK and ERK lev-
els (experiment was repeated
three times). LK25 and AS24
cells plated on CLI and ex-
amined after 10 and 20 min
showed no difference in
ERK activation. The ratio of
phosphoERK to ERK deter-
mined by densitometry was
0.34 and 0.43 for LK25, 10
and 20 min, and 0.37 and 0.39 for AS24 at 10 and 20 min, respectively. (C) Analysis of phospho-JNK. Cells (106) were plated in 6-well
plates as follows: LK25 on PL (lane 1), on FN (lane 2), AS24 on PL (lane 3), on FN (lane 4), and analyzed after 20 min of incubation for
phospho-JNK by Western blotting (the intensities of the bands remained constant for up to 90 min, not shown; experiment was re-
peated twice). (D and E) Effect of FN on cell growth. LK25 (D) or AS24 (E), serum-starved cells were plated at 0.8 3 105 cells/well on
24-well plates coated with 0.04 (diamonds), 0.4 (circles), and 4 (triangles) mg/ml FN and at the indicated times, detached, and counted in
a Coulter counter. Data shown as mean and SD of triplicate determinations (experiments were done three times). * P , 0.01 for all con-
centrations of FN versus uncoated (squares) surface, as determined by ANOVA test.The Journal of Cell Biology, Volume 147, 1999 98
of FN and PL (Fig. 7 D). Therefore, interfering with
uPAR/b1/FN interaction or b1–FN interaction both lead
to a similar block in ERK activation.
Collectively, our experiments show that binding of uPA
to uPAR, by associating predominantly with a5b1 integrin,
forms a complex that signals through MEK1-ERK1/2 acti-
vation, and that high density of uPAR increases this effect.
In an effort to identify additional downstream members of
this cascade, we tested whether Shc and Grb2, previously
described to coimmunoprecipitate with b1 integrin (Wary
et al., 1996, 1998), were in a complex with b1/uPAR immu-
noprecipitates. Although the 52- and 46-kD forms of Shc
and Grb2 could be readily immunoprecipitated from tumor-
igenic or dormant cells (data not shown), we have been
unable so far to find these proteins in complex with b1 in-
tegrins, either in the soluble or insoluble fractions of Tri-
ton X-100 lysates. Similarly, an Src-like tyrosine kinase,
Hck, could be immunoprecipitated from both types of
cells, but was not found to be differentially phosphory-
lated or in complex with b1 integrin (data not shown). We
were also unable to show that, as described previously
(Wary et al., 1996), binding of HEp3 cells to FN induced
Shc phosphorylation (data not shown).
Comparison of ERK Activation In Vivo in Tumorigenic 
and Dormant Cells
In a recent report, active ERK level was shown to be
higher in human renal carcinomas as compared with the
surrounding normal tissue (Oka et al., 1995), suggesting
that the findings in our model system may reflect the situa-
tion in human cancer. Thus, it was of major importance to
test whether the high level of active ERK is present in
the uPAR-rich, tumorigenic cells in vivo. Since the avail-
able anti–phospho-ERK antibodies recognize equally well
chicken and human phospho-ERK (results not shown), to
detect the ERK originating specifically in tumor cells, we
transiently transfected the tumor cells with a construct ex-
pressing HA-tagged ERK2. By immunoprecipitating HA-
ERK2 with anti–HA antibodies and analyzing the precipi-
tate by Western blotting using either anti–HA antibodies
(loading control) or anti–phospho-ERK antibodies, we
showed that HA-ERK expression was maximal at 48 h af-
ter transfection and, as with the native ERK, the level of
phosphorylation of HA-ERK was much greater in LK25
as compared with AS24 cells (Fig. 8 A and results not
shown). To examine the state of ERK phosphorylation in
vivo, 24 h after transfection with HA-ERK, the two tumor-
igenic and two dormant cell types were inoculated on
CAMs and incubated in vivo for an additional 24 h. The
areas of CAM containing tumor cells were excised, lysed,
subjected to IP with anti–HA antibodies, and analyzed by
Western blotting for HA-ERK2 and phospho-ERK con-
tent. Fig. 8 B shows that the level of phosphorylated
ERK2 was three to sixfold greater in T-HEp3 and LK 25
cells than in D-HEp3 and AS24 dormant cells, respec-
tively, indicating that the difference in the signal leading to
ERK activation was maintained in vivo.
Figure 6. Physical and functional association between uPAR
and a5b1 integrin. (A) Coimmunoprecipitation of b1-integrin
and uPAR. T-HEp3, D-HEp3, or AS24 cells were lysed in Tri-
ton X-100 buffer (see Materials and Methods), centrifuged, and
the pellets were extracted with RIPA buffer. Cell proteins (400
mg) were mixed with anti–b1 antibody (TS2/16) or G beads (G-
control) or isotype-matched mouse IgG (IgG-control) and the
resulting IPs were analyzed by Western blotting with anti–b1
integrin antibodies (upper panel) or anti–uPAR antibodies
(lower panel) (experiment was repeated twice). (B, left) Cells
were surface-biotinylated and the cell extracts were subjected
to IP with anti-a5b1 (BIIG2), anti-uPAR (R2), anti-a5 (P1D6),
or with isotype-matched IgG antibodies and analyzed by
streptavidin-HRP binding to biotinylated proteins after SDS-
PAGE and transfer to PVDF membranes. The arrows on the
left indicate the positions of a5, b1, and uPAR. (B, right) Sur-
face-biotinylated proteins were immunoprecipitated with anti–
b1 antibodies (TS2/16) and the biotinylated coimmunoprecipi-
tating proteins were detected as described above. The arrows
indicate the position for a integrin, b1 integrin, and uPAR. (C)
Western blot for b1 integrin from whole cell lysates from the
two tumorigenic (T-HEp3 and LK25) or the two dormant (D-
HEp3 and AS24) cell lines. The arrows indicate the position of
b1 and pre-b1 integrin.Aguirre Ghiso et al. Role of uPAR, Integrins, and MAPK in Tumor Dormancy 99
Does Interference with the Function of uPAR/b1/FN 
Signaling Complex Affect the Growth of Tumorigenic 
Cells In Vivo?
Our results indicate that a functional association between
a5b1 integrins and uPAR in tumorigenic cells with a full
complement of uPAR is necessary for their optimal adhe-
sion to FN and for transducing the FN-dependent activa-
tion of ERK. Therefore, we asked whether inhibition of
ERK-activation by b1 integrin function–blocking antibod-
ies (AIIB2) (Fig. 7 D) and/or antibody to uPAR (R2) (Fig.
7 B), will reduce cell proliferation in vivo. Cells were pre-
treated with the appropriate antibodies, inoculated on the
CAMs, and the number of tumor cells per CAM was de-
termined on day 1, 3, and 7 postinoculation. Regardless of
treatment, on day 1, only slightly more than a third of the
inoculum was recoverable from the CAMs. On day 3,
while the T-HEp3 cells, either untreated, or pretreated ei-
ther with nonimmune IgG or irrelevant antibody (anti-
CD55, CD55 is expressed in HEp3 cells, results not
shown) underwent at least two divisions, cells pretreated
either with anti–uPAR (R2), anti–b1 (AIIB2), or both an-
tibodies, underwent only z0.5 divisions (Fig. 8 C). The
combination of antibodies exerted a slightly stronger in-
hibitory effect than each antibody individually. The num-
ber of cells on day 7 of in vivo incubation was similar in all
groups indicating that the effect was transient. These re-
sults show that by interfering with the uPAR/b1/FN sig-
naling complex that activates ERK, we can mimic the ef-
fect of uPAR deficiency, and that disruption and reduced
abundance of this signaling complex may be responsible
for the dormancy of uPAR-deficient cells.
Figure 7. Effect of b1-integrin–uPAR complex disruption and suPAR treatment on ERK activation. (A) Effect of soluble uPAR on
ERK activation. LK25 (top panels) or AS24 (bottom panels) monolayers were serum-starved for 24 h and incubated with suPAR for 5
min in the presence of 200 KIU/ml of aprotinin. The cells were lysed and the proteins were analyzed for phospho-ERK and ERK levels
(experiment was repeated three times). (B) Effect of anti–uPAR antibodies on ERK activation. T-HEp3 cells were incubated in sus-
pension with medium alone (lanes 1 and 2), 7 mg/ml of isotype-matched IgG (lane 3), or with 7 mg/ml of anti–uPAR antibody (R2, lane
4) at 378C for 35 min and inoculated into plates coated with 4 mg/ml PL (lane 1) or FN (lanes 2–4), allowed to adhere for 10 min, lysed,
and analyzed for phospho-ERK (upper panel) and ERK (lower panel) levels. The numbers on top of each lane show the ratio of phos-
pho-ERK/ERK determined by densitometry. (Experiment repeated twice). (C) Effect of peptide 25 (P25) on ERK phosphorylation.
Subconfluent monolayers of T-HEp3 cells were treated with peptide 25 or its scrambled version (SP25) for 10 min, the cells were lysed,
and phospho-ERK and ERK levels were determined. (D) Effect of anti–b1 antibody and peptide 25 on adhesion-activated ERK. Sus-
pensions of T-HEp3 cells were incubated with or without anti–b1 antibodies (AIIB2) or isotype-matched IgG for 30 min, the cells
plated on plastic plates coated with 4 mg/ml of PL or a combination of PL 1 4 mg/ml FN and after 15 min tested for phospho-ERK
and ERK levels. In addition, T-HEp3 cells were plated on FN in the presence or absence of 5 mM peptide 25 and tested as above.The Journal of Cell Biology, Volume 147, 1999 100
Discussion
We have previously shown that downregulation of surface
uPAR expression in human carcinoma cells, brings about
a state of tumor dormancy characterized by cancer cell
survival unaccompanied by an increase in tumor mass.
This outcome is the result of a reduced proliferation rate
and not of increased apoptosis (Yu et al., 1997). We set out
to explore the mechanism through which a reduction in
uPAR can evoke such dramatic changes. The proposed
hypothesis stated that only levels of uPAR above a given
threshold will, when saturated by uPA and laterally inter-
acting with a putative transmembrane partner(s), initiate
an outside-in signaling cascade capable of maintaining
cancer cells in a proliferative state in vivo. A reduction in
the surface expression of uPAR should restrict the magni-
tude of this signal, leading to dormancy.
We were able to show that uPAR is physically associ-
ated with an FN-binding integrin, a5b1. Since low uPAR
cells express similar or greater levels, of a5b1 than uPAR-
rich cells, it could not be their mere physical presence on
the cell surface that affects the behavior of uPAR-rich and
low uPAR cells. Therefore, we concluded that in uPAR-
rich cells a5b1 integrin, through its interaction with
uPAR, must be held in an active state. The high level of
uPAR leads to an in increase in the proportion of integrins
sequestered into these interactions exceeding a threshold
necessary for effective adhesion to FN, FN-dependent ac-
tivation of ERK, and cell proliferation in vivo.
Cell cycle progression analysis of the uPAR-rich (T-
HEp3 cells) and low uPAR (D-HEp3) cells in culture and
in vivo indicated that a reduction in uPAR expression ren-
ders the cells either incapable to respond to, or unable to
generate a sufficient signal to propel them through G0/G1
in vivo. This was underscored by the fact that in culture,
the proportion of cells in the different cell cycle phases
was similar, whereas only after 24–48 h of in vivo expo-
sure, the proportion of cells in G0/G1 in D-HEp3 cells rap-
idly increased and the G2/M and S phases declined. In con-
trast, the S phase fraction of T-HEp3 cells significantly
increased and the G0/G1 consistently declined (Fig. 1, C
and D). Our findings (Figs. 2 A and 8 B) strongly suggest
that the in vivo growth arrest of the uPAR-deficient cells
is due to an interruption of the pathway to ERK activa-
tion. However, as indicated by the inhibition of ERK acti-
vation and growth of uPAR-deficient cells by a specific
MEK1 inhibitor (Fig. 2 B), the low level of active ERK in
these cells is sufficient to promote their growth in culture.
This is not unexpected as most normal cell lines proliferate
rapidly in culture, but do not develop tumors in nude mice,
syngeneic animals, or the CAM of chick embryos. These
cells become tumorigenic when transformed by oncogenic
Figure 8. Analysis of ERK activation and the role of b1-integrin/
uPAR signaling in vivo. (A) HA-ERK expression and phosphor-
ylation in culture. LK25 (lanes 1, 2, and 4) or AS24 (lane 3) cells
were either transfected (lanes 2, 3, and 4) or mock-transfected
(lane 1) with 10 mg of expression vector coding for hemaggluti-
nin-tagged ERK2 (HA-ERK2). After 48 h in culture, cell lysates
were subjected to IP with an anti–HA antibody (lanes 1–3) or
isotype-matched IgG (lane 4). IPs were analyzed by Western
blotting using either anti–HA antibodies (lower panel) or anti
phospho-ERK antibodies (upper panel) (experiment was re-
peated three times). (B) HA-ERK expression and phosphoryla-
tion in vivo. T-HEp3 (lanes 1, 2, and 6), LK25 (lane 3), D-HEp3
(lane 4), or AS24 (lane 5) cells were transfected as in A but, after
24 h in culture, the cells were detached and inoculated on the
CAMs (2.5 3 106 cells/CAM, see Materials and Methods). After
24 h of growth in vivo, the CAMs containing tumor cells were an-
alyzed by IP using anti–HA antibodies (lanes 1–5) or isotype-
matched IgG (lane 6). HA-ERK2 was determined by Western
blotting with anti–HA (lower panel) and its level of phosphoryla-
tion with anti–phospo-ERK antibody (upper panel). The num-
bers below lanes 2 and 3 in A and 2, 3, 4, and 5 in B indicate the
ratio of phospho-HA-ERK2/HA-ERK2 determined by densi-
tometry. (C) The effect of anti-b1 blocking antibody or anti-
uPAR (domain 3) antibody on T-HEp3 proliferation in vivo.
T-HEp3 cells were incubated for 40 min with medium alone (C), 15
mg/ml of isotype-matched IgG (IgG), 15 mg/ml of anti–CD55/
DAF mAb (CD55), 7 mg/ml of monoclonal anti-uPAR (R2) anti-
body, 10 mg/ml of anti-b1 blocking mAb (AIIB2) or R2 1 AIIB2
(same concentrations, R2/AIIB2). Cells (106 HEp3 cells/CAM)
were inoculated on CAMs of 9-d-old chick embryos and, after 3 d,
the number of cells per tumor was determined (see Materials and
Methods). (R2, AIIB2, and antibody combination treatment was
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viruses known to hyperactivate, among others, the ERK
pathway. It is also possible that other MAP kinases, such
as JNK, which we showed to be equally active in both cell
types, may contribute to cell cycle progression in culture.
The observed difference in ERK activation in vitro and in
vivo correlates with the findings showing that primary le-
sions of human renal cell carcinoma display hyperacti-
vated ERK1/2 (Oka et al., 1995).
uPAR, a GPI-linked protein has been previously shown
to associate with, and modulate the function of integrins
from three different families (b1, 2, and 3) (Xue et al.,
1994, 1997; Wei et al., 1996). We confirmed the physical
association of uPAR and a5b1 integrin in HEp3 cells by
co-IP experiments with anti–a5,  b1, or a5b1 antibodies
(Fig. 6, A and B). By comparing the effect of MnCl2 and
anti-b1 activating antibodies (TS2/16), known inducers of
integrin activation, we determined that, as measured by
cell binding to FN, the a5b1 integrins in uPAR-rich cells
were constitutively active and resistant to further stimula-
tion. In low uPAR cells the integrins were inactive but re-
sponsive to stimulation. This difference in integrin avidity
had an important consequence for intracellular signal
transduction: the attachment of uPAR-rich cells to FN was
accompanied by a persistent (up to 90 min) increase in the
level of phospho-ERK, followed by increased cell prolifer-
ation in serum-free medium (Fig. 5, A and D). In low
uPAR cells, the amount of uPAR–a5b1 integrin complex
was greatly reduced, the adhesion to FN was low, the max-
imal ERK stimulation by FN was greatly diminished in
scope and duration (Fig. 5 A), and no effect on cell prolif-
eration was noted (Fig. 5 E). We tentatively concluded
that since both cell types have similar levels of a5b1 (Fig.
4 B), that it is the high density of uPAR in T-HEp3 and
LK25 cells that, through lateral interactions with a5b1, is
responsible for the initiation of signal transduction events
leading to ERK activation and cell proliferation. This re-
sponse appears to be specific for FN integrins, since no dif-
ferential response with regard to effect of attachment on
ERK activation was found between uPAR-rich and low
uPAR cells adherent to CLI. (Fig. 5 B, see legend). Our
findings are in agreement with published evidence show-
ing a proximity by resonance energy transfer technique of
uPAR and b1 integrin in HT1080 fibrosarcoma cells (Xue
et al., 1997), which like T-HEp3 and LK25 cells form large,
progressively growing tumors on CAMs (Kim et al., 1998).
The growth of other cancer cells, such as primary and met-
astatic melanomas (Mortarini et al., 1992) and colon carci-
noma HT29 (Varner et al., 1995), showed an a5b1-medi-
ated stimulation of cell growth on FN but the level of
uPAR in these cells was not tested. Also, growth inhibi-
tion in nude mice was observed in transformed bronchial
epithelium treated with anti–a5b1 antibodies (Schiller and
Bittner, 1995).
If ERK activation is dependent on the abundance of
uPAR, it should theoretically be possible, by adding
suPAR to uPAR-deficient cells, to increase the frequency
of lateral interactions between uPAR and a5b1 and, thus,
ERK activation. Indeed, we found that incubation of
uPAR-deficient cells with 5 ng/ml of suPAR-stimulated
ERK activation (Fig. 6 B), indicating that even when not
anchored in the plasma membrane, uPAR can affect signal
transduction and, possibly, in vivo proliferation of cancer
cells. This may have importance in cancer progression as
high levels of circulating suPAR have been shown to be
associated with some cancers (Sier et al., 1998) and may,
by binding to cells in existing metastatic foci, stimulate
their growth.
Previous reports from our and other laboratories have
shown that binding of pro-uPA to its receptor results in a
de novo association of various intracellular proteins, such
as nonreceptor tyrosine kinases (Busso et al., 1994; Bo-
huslav et al., 1995; Konakova et al., 1998), with uPAR (as
determined by their co-IP with anti–uPAR antibodies),
and that uPA binding can initiate signal transducing
events (Nguyen et al., 1998; Tang et al., 1998). Although,
the mechanism responsible for these effects has not been
elucidated, one possible explanation may be that binding
of pro-uPA to uPAR may change its conformation and as
a result, change the nature of its interactions with spe-
cific, signal transducing transmembrane proteins such as
integrins. We used several reagents, including pro-uPA,
antibodies to domain 3 of uPAR (Ronne et al., 1991),
and a peptide that has been shown previously to disrupt
interactions between b1 integrins and uPAR (Wei et al.,
1996, 1999) to explore their potential effect on ERK acti-
vation. Treatment of uPAR-rich cells with low pro-uPA
concentrations (1 nM, equivalent to the Kd value for
uPAR binding in these cells) produced a level of active
ERK that was 33-fold greater than the maximal level of
active ERK produced by 80 times higher scuPA concen-
tration in low uPAR cells (Fig. 3, A and C). This supports
our hypothesis that only when uPAR–integrin interac-
tions are frequent enough, can substantial ERK activa-
tion be achieved. In uPAR-rich cells, this is achieved
even when only a fraction of the receptors is uPA-bound,
whereas in low uPAR cells, only when most of the uPAR
is uPA-bound, some degree of stimulation is observed,
explaining the need for high uPA concentrations. In sup-
port of this conclusion, we showed that the antibody to
domain 3 of uPAR reduced ERK activation upon cell ad-
hesion to FN (Fig. 6 C). Also, a peptide shown previously
to disrupt uPAR–b1 interaction (Wei et al., 1996) pro-
duced a dose-dependent reduction of ERK activation in
tumorigenic cells, without affecting adhesion to FN. In
contrast to our findings, the authors of this study con-
cluded that uPAR–b1 interaction deactivates the integrin
and blocks adhesion to FN. While our manuscript was in
preparation, Wei et al. (1999) have published results sim-
ilar to ours, in which uPAR–b1 interaction led to ERK
activation on FN in smooth muscle cells and peptide 25
disrupted this function without affecting adhesion. The
authors ascribed this controversy in their findings to the
caveolin content of different cells, suggesting that other
proteins may participate in the uPAR–integrin complex.
However, we found caveolin not to be present in extracts
of either tumorigenic or dormant cells tested by Western
blotting (results not shown), suggesting that integrin acti-
vation may depend on specific cellular contexts. In our
cells, the lateral interaction of uPAR with a5b1 in the
presence of uPA, is capable of keeping the MEK-ERK
pathways constitutively active and the uPAR-rich cells
proliferating on FN.
We have only began our inquiry into the additional
components of the signal transduction pathway that leadsThe Journal of Cell Biology, Volume 147, 1999 102
from a5b1 to ERK activation. Published reports (Wary
et al., 1996, 1998) showed that phosphorylation of the
adapter molecule Shc, and recruitment of Grb2 are in this
pathway, and that Shc can be coimmunoprecipitated with
b1 integrins. However, we did not yet find that adhesion of
uPAR-rich cells to FN leads to Shc phosphorylation or
that Shc coimmunoprecipitates with b1 integrins in uPAR-
rich or -poor cells. The participation of Shc may depend on
the cell type or on the experimental conditions, since other
authors have also failed to detect Shc phosphorylation
upon adhesion to FN (Zhao et al., 1998; Wei et al., 1999).
It remains possible that only very potent cross-linking,
such as that induced by antibodies immobilized on beads
(Wary et al., 1996, 1998), is needed to detect Shc in anti-b1
immunoprecipitates. Similarly, we could not detect activa-
tion of Hck, the Src-like kinase, reported to occur upon
DFP-uPA treatment of other tumor cells (Konakova et al.,
1998), or its association with b1 integrin. Although JNK
activation may be involved in promoting cell cycle pro-
gression on LN (Mainiero et al., 1997), we did not find that
JNK was activated when cells were plated on FN for 20
min, pointing so far to ERK as the main participant. We
cannot exclude a role for other kinases such as Src, Fyn,
Yes, Lck, FAK (Lin et al., 1997; Zhao et al., 1998; Wary et al.,
1998), or the integrin linked kinase (Radeva et al., 1997),
which have been reported to influence cell cycle progres-
sion (Wu et al., 1998).
Finally, since we showed that a high level of uPAR, its
association with uPA, and adhesion of cells to FN, con-
verge to generate strong ERK activation, which is main-
tained in vivo, we tested and found that the interruption
of this signal transiently inhibited in vivo proliferation.
Therefore, a rapid, FN-induced ERK activation must take
place for the cells to enter and progress through the cell
cycle in vivo. Interruption of this signal mimics, at least
transiently, the initial steps responsible for the state of
dormancy.
In summary, we have found that, when present at a high
level, uPAR interacts and holds the integrin a5b1 in an ac-
tive state. Adhesion to FN organizes a signaling complex
leading to a full activation of MEK1/ERK. It appears that
only when a signal above a certain threshold is generated
by the combined effect of uPA/uPAR/a5b1 and FN, the
cells are capable of in vivo growth. As uPAR-rich and low
uPAR cells produce similar amounts of uPA (Yu et al.,
1997), and express similar levels of a5b1 (Fig. 4 B), the
observed difference in signaling must be dependent on
uPAR levels. When the cascade is interrupted or dimin-
ished, as with anti–uPAR or anti–b1 antibodies or by
downregulation of uPAR, the signaling complex switches
to the off state and the cells become unable to grow in
vivo. A somewhat similar situation was described in breast
cancer (Wang et al., 1998), where a cross-talk between the
EGF receptor and b1 integrins kept the cells in a tumori-
genic mode with high ERK activation. When the aberrant
b1, EGF receptor, or ERK signaling was corrected, tu-
mor cells underwent differentiation and stopped growing.
However, to the best of our knowledge, ours is the first
published report in which induction of tumor dormancy in
vivo was shown to be dependent on blocking the function
of FN-dependent uPA/uPAR/b1 signal leading to MEK/
ERK activation.
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